Tozinameran (BNT162b2) Vaccine : The Journey from Preclinical Research to Clinical Trials and Authorization
Vaccination development and production was an essential question for the prevention and global control of COVID-19. The strong support from governing authorities such as Operation Warp Speed and robust funding has led to the development and authorization of the tozinameran (BNT162b2) vaccine. The BNT162b2 vaccine is a lipid nanoparticle-encapsulated mRNA that encodes for SARS-CoV-2 spike protein, the main site for neutralizing antibodies. Once it binds with the host cells, the lipid nanoparticles enable the transfer of the RNA, causing S antigens' expression of the SARS-CoV-2, conferring immunity. The vaccine is administered as a 2-dose regime 21 days apart for individuals 16 years and older. Pfizer-BioNTech's BNT162b2 vaccine was the first candidate to receive FDA-Emergency Use Authorization (EUA) on December 11, 2020. During phase 2/3 clinical trials, 95% efficacy was reported among 37,706 participants over the age of 16 who received the BNT162b2 vaccination; additionally, 52% efficacy was noted 12 days following the administration of the first dose of BNT162b2, reflecting early protection of COVID-19. The BNT162b2 vaccine has exhibited 100% efficacy in clinical trials of adolescents between the ages of 12 and 15. Clinical trials in pregnant women and children under the age of 12 are expected to also exhibit promising results. This review article encompasses tozinameran (BNT162b2) vaccine journey, summarizing the BNT162b1 and BNT162b2 vaccines from preclinical studies, clinical trial phases, dosages, immune response, adverse effects, and FDA-EUA.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:22 |
|---|---|
| Enthalten in: |
AAPS PharmSciTech - 22(2021), 5 vom: 07. Juni, Seite 172 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Khehra, Nimrat [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 14.06.2021 Date Revised 18.02.2022 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1208/s12249-021-02058-y |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM326483128 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM326483128 | ||
| 003 | DE-627 | ||
| 005 | 20231225194709.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1208/s12249-021-02058-y |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1088.xml |
| 035 | |a (DE-627)NLM326483128 | ||
| 035 | |a (NLM)34100150 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Khehra, Nimrat |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Tozinameran (BNT162b2) Vaccine |b The Journey from Preclinical Research to Clinical Trials and Authorization |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.06.2021 | ||
| 500 | |a Date Revised 18.02.2022 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Vaccination development and production was an essential question for the prevention and global control of COVID-19. The strong support from governing authorities such as Operation Warp Speed and robust funding has led to the development and authorization of the tozinameran (BNT162b2) vaccine. The BNT162b2 vaccine is a lipid nanoparticle-encapsulated mRNA that encodes for SARS-CoV-2 spike protein, the main site for neutralizing antibodies. Once it binds with the host cells, the lipid nanoparticles enable the transfer of the RNA, causing S antigens' expression of the SARS-CoV-2, conferring immunity. The vaccine is administered as a 2-dose regime 21 days apart for individuals 16 years and older. Pfizer-BioNTech's BNT162b2 vaccine was the first candidate to receive FDA-Emergency Use Authorization (EUA) on December 11, 2020. During phase 2/3 clinical trials, 95% efficacy was reported among 37,706 participants over the age of 16 who received the BNT162b2 vaccination; additionally, 52% efficacy was noted 12 days following the administration of the first dose of BNT162b2, reflecting early protection of COVID-19. The BNT162b2 vaccine has exhibited 100% efficacy in clinical trials of adolescents between the ages of 12 and 15. Clinical trials in pregnant women and children under the age of 12 are expected to also exhibit promising results. This review article encompasses tozinameran (BNT162b2) vaccine journey, summarizing the BNT162b1 and BNT162b2 vaccines from preclinical studies, clinical trial phases, dosages, immune response, adverse effects, and FDA-EUA | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a BNT162b1 | |
| 650 | 4 | |a BNT162b2 | |
| 650 | 4 | |a BioNTech | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Pfizer | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a adolescents | |
| 650 | 4 | |a adverse effects | |
| 650 | 4 | |a antibody response | |
| 650 | 4 | |a children | |
| 650 | 4 | |a clinical trials | |
| 650 | 4 | |a efficacy | |
| 650 | 4 | |a phase 1 trials | |
| 650 | 4 | |a phase 1/2 trials | |
| 650 | 4 | |a phase 2 trials | |
| 650 | 4 | |a phase 2/ 3 trials | |
| 650 | 4 | |a phase 3 trials | |
| 650 | 4 | |a preclinical trials | |
| 650 | 4 | |a pregnant women | |
| 650 | 4 | |a real-world outcomes | |
| 650 | 4 | |a safety | |
| 650 | 4 | |a tozinameran | |
| 650 | 4 | |a vaccine | |
| 650 | 7 | |a Antibodies, Neutralizing |2 NLM | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 650 | 7 | |a Spike Glycoprotein, Coronavirus |2 NLM | |
| 650 | 7 | |a spike protein, SARS-CoV-2 |2 NLM | |
| 650 | 7 | |a BNT162 Vaccine |2 NLM | |
| 650 | 7 | |a N38TVC63NU |2 NLM | |
| 700 | 1 | |a Padda, Inderbir |e verfasserin |4 aut | |
| 700 | 1 | |a Jaferi, Urooj |e verfasserin |4 aut | |
| 700 | 1 | |a Atwal, Harshan |e verfasserin |4 aut | |
| 700 | 1 | |a Narain, Shreya |e verfasserin |4 aut | |
| 700 | 1 | |a Parmar, Mayur S |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t AAPS PharmSciTech |d 2000 |g 22(2021), 5 vom: 07. Juni, Seite 172 |w (DE-627)NLM126699429 |x 1530-9932 |7 nnns |
| 773 | 1 | 8 | |g volume:22 |g year:2021 |g number:5 |g day:07 |g month:06 |g pages:172 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1208/s12249-021-02058-y |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 22 |j 2021 |e 5 |b 07 |c 06 |h 172 | ||